EpiCept to Report Third Quarter 2008 Operating and Financial Results on November
7, 2008
TARRYTOWN, N.Y.--(BUSINESS WIRE)—Nov. 5, 2008--Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss third quarter
2008 operating and financial results on Friday, November 7, 2008 at
9:00 a.m. Eastern time. The call will follow the release of these
financial results earlier in the day at 12:01 a.m. Eastern time.
To participate in the live call, please dial from the U.S. or
Canada (877) 494-5472 or from international locations (706) 758-9407
(please reference access code 72317253). The conference call will also
be broadcast live on the Internet and may be accessed at
www.epicept.com. The web cast will be archived for 90 days.
A telephone replay of the call will be available for seven days by
dialing from the U.S. and Canada (800) 642-1687 or from international
locations (706) 645-9291 (please reference reservation number
72317253).
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of cancer and
pain. The Company's broad portfolio of pharmaceutical product
candidates includes Ceplene, a cytokine immunomodulator that recently
received final marketing approval from the EMEA for the remission
maintenance of AML patients and several pain therapies in clinical
development. In addition, EpiCept's ASAP technology, a proprietary
live cell high-throughput caspase-3 screening technology, can
efficiently identify new cancer drug candidates and molecular targets
that selectively induce apoptosis in cancer cells. Two oncology drug
candidates currently in clinical development that were discovered
using this technology have also been shown to act as vascular
disruption agents in a variety of solid tumors.
Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of
historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. Factors that may cause actual results
or developments to differ materially include: the risk that Ceplene(R)
will not be launched in Europe in the first quarter of 2009 or achieve
significant commercial success, the risk that we are unable to find a
suitable marketing partner for Ceplene(R) on attractive terms, a
timely basis or at all, the risk that any required post-approval
clinical study will not be successful, the risk that EpiCept will not
be able to maintain its final regulatory approval or marketing
authorization, the risks associated with the adequacy of our existing
cash resources, our need to raise additional financing to continue to
meet our capital needs and our ability to continue as a going concern,
the risks associated with our ability to continue to meet our
obligations under our existing debt agreements or that we may default
on our loans or that our lenders may declare the Company in default,
the risk that the Company's securities may be delisted by The Nasdaq
Capital Market or the OMX Nordic Exchange, the risk that Myriad's
development of Azixa(TM) will not be successful, the risk that
Azixa(TM) will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant
payments under our agreement with Myriad, the risk that the
development of our other apoptosis product candidates will not be
successful, the risk that our ASAP technology will not yield any
successful product candidates, the risk that clinical trials for NP-1,
including our current clinical trial in PHN, or EPC2407 will not be
successful, the risk that NP-1 or EPC2407 will not receive regulatory
approval or achieve significant commercial success, the risk that our
other product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risks associated with
our dependence upon key personnel, the risks associated with reliance
on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product
candidates; the cost, delays and uncertainties associated with our
scientific research, product development, clinical trials and
regulatory approval process; our history of operating losses since our
inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material
risks are more fully discussed in EpiCept's periodic reports,
including its reports on Forms 8-K, 10-Q and 10-K and other filings
with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in EpiCept's
filings, which are available at www.sec.gov or at www.epicept.com. You
are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.
###
EPCT-GEN
*Azixa is a registered trademark of Myriad Genetics, Inc.
CONTACT: EpiCept Corporation
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
EpiCept to Report Third Quarter 2008 Operating and Financial Results on November 7, 2008
| Source: Immune Pharmaceuticals Inc
Attachments
